Lithium toxicity with prolonged neurologic sequelae following sleeve gastrectomy

A case report and review of literature

Yi-Hsin Lin, MD*a, Sheng-Wen Liu, MD*b, Hsien-Lin Wu, MD$c, Jung-Cheng Kang, MD*d, Kuo-Yang Huang, MD*e, Hsuan Huang, MD*f,g

Abstract

Rationale: Lithium is the first-line medication for bipolar disorder, given a narrow therapeutic window of 0.8 to 1.2 mEq/L. Change of lithium pharmacokinetics following bariatric surgery may lead to lithium toxicity, which is particularly concerned.

Patient concerns: We presented a 39-year-old man with morbid obesity and bipolar affective disorder for 20 years, who was treated with lithium. He developed serious lithium toxicity following sleeve gastrectomy and prolonged neurologic sequelae.

Diagnoses: He suffered from persistent watery diarrhea, general weakness, and then drowsy consciousness. Lithium level was checked immediately to be 3.42 mEq/L and lithium toxicity was diagnosed.

Interventions: After 3 courses of hemodialysis, his serum lithium level subsequently declined to 0.63 mEq/L, while his consciousness returned normal. Lithium was replaced by lamotrigine.

Outcomes: The patient was discharged thirty-five days after admission, while his serum lithium declined to 0.06 mEq/L. Neurologic sequelae were noted by muscle weakness and pain sensation in both feet. The nerve conduction test revealed sensorimotor polyneuropathy with conduction block. He was advised to keep a passive range of motion exercise.

Lessons: Although the consensus guideline remains lacking, our report reviewed cases of relevance in the literature and highlighted the awareness of the potential risk of lithium toxicity following bariatric surgery. We suggest close monitoring of the lithium levels and perhaps a dosage adjustment for the postoperative period.

Abbreviations: RYGB = Roux-en-Y gastric bypass, SG = sleeve gastrectomy.

Keywords: bariatric surgery, lithium toxicity, neurologic sequelae, sleeve gastrectomy

1. Introduction

Patients with bipolar disorder are more frequently associated with binge eating and obesity than the general population. McElroy et al reported that 14.3% of patients with bipolar disorder had at least one-lifetime comorbid eating disorder, in which binge eating disorder was the most common (8.8%) and associated with obesity and severe obesity.[1] Nowadays, bariatric surgery is the most effective treatment for morbid obesity to reduce obesity-related comorbidity and total mortality.[2] Vertical sleeve gastrectomy (SVG) reduces substantial gastric volume by resection of a large portion of the stomach, and then patients achieve body weight loss. SG, accounting for 58% of bariatric surgery performed in the United States in 2016, has surpassed Roux-en-Y gastric bypass (RYGB) to become the most popular choice among all bariatric procedures.[3,4] Notedly, around two-thirds of patients presenting for bariatric surgery received a psychiatric diagnosis, the most common of which was major depressive disorder.[5] More than one-third of them took some psychiatric medication.[5,6]

Lithium is an effective mood stabilizer that is used as the first-line medication for bipolar disorder, given a narrow therapeutic window of 0.8 to 1.2 mEq/L.[7,8] A study in Canada disclosed that the prevalence of lithium medication among patients undergoing assessment for bariatric surgery was around 1.2%.[9] Change of lithium pharmacokinetics following bariatric surgery may lead to lithium toxicity, which is particularly concerned. We presented a case of serious lithium toxicity following SG and prolonged neurologic sequelae. Our report highlighted the awareness of the
Lithium 3.42 mEq/L
Hemoglobin 10.6 g/dL
Pancreas enzymes Normal
Cardiac enzymes Normal
S-GPT 8 IU/L
HCO3 26 mmol/L
Cl 111 mmol/L
K 2.6 mmol/L
Na 137 mmol/L
Lactic acid 3.1 mg/dL
C.R.P. 2.3 mg/dL

On the third day of admission, our patient was admitted for aggressive intravenous hydration. On the third day of admission, our patient, a case of morbid obesity, was sent to our hospital due to persistent watery diarrhea, dehydration, and general weakness for 3 days. Upon the arrival at our hospital, his vital signs were blood pressure 117/57 mm Hg, pulse rate 108/min, respiratory rate 18/min, body temperature 37.1°C. Electrocardiography showed sinus tachycardia. The laboratory data revealed severe hypokalemia (K 2.6 mmol/L [3.6–5.1]), acute kidney injury (Bun 29 mg/dL [8–20], Cr 4.36 mg/dL [0.44–1.03]) estimated Glomerular filtration rate 16 [mL/min]), and normal liver, pancreas, cardiac enzymes as well as other electrolytes (Na 137 mmol/L [136–144], Cl 111 mmol/L [100–111], bicarbonate 26 mmol/L [22–26]) (Table 1). Other positive findings were mild anemia and leukocytosis (white blood cell 10.1 × 103/uL [3.8–10.0]). Hemoglobin 10.6 g/dL [12–16], elevated C-Reactive protein 2.3 mg/dL (<1.0) and lactic acid 3.1 mmol/L (0.5–2.2).

He was admitted for aggressive intravenous hydration. On the third day of admission, the patient’s potassium level (3.2 mmol/L) and kidney function (Bun 23 mg/dL, Cr 2.57 mg/dL, eGFR 30 mL/min) were getting better, but he was getting deteriorated with drowsy consciousness. The brain computed tomography revealed no significant findings. Tracking his medical history, he was diagnosed as a bipolar affective disorder for 20 years. He was under regular follow-up in the psychiatric clinic with lithium carbonate 600 mg twice daily, risperidone 2 mg twice daily, and flurazepam 60 mg once daily. He was still taking the same dosage during these days after surgery. Lithium level was found to be 3.42 mEq/L and lithium toxicity was diagnosed. Lithium carbonate was discontinued immediately, and urgent hemodialysis was suggested by nephrologist.

After 3 courses of hemodialysis, his serum lithium level subsequently declined to 0.63 mEq/L and creatinine level to 1.58 mg/dL, while his consciousness returned normal. In the following days, neurologic sequelae were noted by muscle weakness (muscle power 2 points over bilateral dorsiflexors and plantarflexors) and pain sensation in both feet. The nerve conduction test revealed sensorimotor polyneuropathy with conduction block. The patient was discharged thirty-five days after admission, while his serum lithium and creatinine level declined to 0.06 mEq/L and 1.05 mg/dL, respectively. He was advised to keep a passive range of motion exercise until the nerve function recovers. Lithium carbonate was replaced by lamotrigine now.

### Table 1

| Item               | Result               | Reference |
|--------------------|----------------------|-----------|
| Bun                | 29 mg/dL             | 8–20 mg/dL|
| Cr                 | 4.36 mg/dL           | 0.44–1.03 mg/dL |
| S-GPT              | 8 IU/L               | 6–45 IU/L |
| Na                 | 137 mmol/L           | 136–144 mmol/L |
| K                  | 2.6 mmol/L           | 3.6–5.1 mmol/L |
| Cl                 | 111 mmol/L           | 100–111 mmol/L |
| HCO3               | 26 mmol/L            | 22–26 mmol/L |
| Cardiac enzymes    | Normal               | –         |
| Pancreas enzymes   | Normal               | –         |
| Hemoglobin         | 10.6 g/dL            | 12–16 g/dL |
| WBC                | 10.1 × 10^3/uL       | 3.8–10.0 × 10^3/uL |
| C.R.P.             | 2.3 mg/dL            | ≤1.0 mg/dL |
| Lactic acid        | 3.1 mg/dL            | 0.5–2.2 mg/dL |
| Lithium            | 3.42 mEq/L           | 0.6–1.2 mEq/L |
because lithium takes the time to be absorbed and to penetrate the central and peripheral nervous system. In some cases, neurologic complications did not disappear despite the successful removal of lithium by hemodialysis.\textsuperscript{[21,22]} These prolonged neurologic sequelae consist of cerebellar dysfunction, extrapyramidal symptoms, brainstem dysfunction, dementia, nystagmus, choreoathetoid movements, myopathy, and blindness.\textsuperscript{[21,22]} Demyelination in the nerve system was proposed as the cause, which was consistent with the nerve conduction test report of our patient, sensorimotor polyneuropathy with conduction block. The prolonged neurologic sequelae could continue for months and, in rare cases, for years.\textsuperscript{[21,23]}

On account of the narrow therapeutic window of lithium, as well as the dramatic changes in oral intake and fluid status following bariatric surgery, caution should be taken in managing patients who take lithium. A protocol has been proposed by a previous literature, the authors of which suggest checking lithium levels weekly during the first 6 postoperative weeks, then every 2 weeks until 6 months postsurgery, and later monthly until 1-year postsurgery.\textsuperscript{[13]} Although the consensus guideline remains lacking, close monitoring of lithium levels and perhaps a dosage adjustment are necessary for the postoperative period.

4. Conclusion

Patients on lithium undergoing SG or other bariatric procedures should be informed of the potential risk of lithium intoxication and its symptoms. Surgeons and psychiatrists should be alert to the signs and symptoms of lithium intoxication, especially for gastrointestinal problems which resemble the side effects of bariatric surgery and therefore could be misleading. Finally, further studies on lithium pharmacokinetics following bariatric surgery are needed to determine the most appropriate protocol for patients who take lithium and will undergo bariatric surgery.

Acknowledgments

The authors would like to thank all the people who participated in this study. The authors also are grateful to the hospital officials for providing support for this study.

Author contributions

Data curation: Yi-Hsin Lin, Sheng-Wen Liu, Hsein-Lin Wu, Jung-Cheng Kang.
Investigation: Yi-Hsin Lin, Sheng-Wen Liu, Kuo-Yang Huang.
Resources: Hsein-Lin Wu.
Supervision: Jung-Cheng Kang, Kuo-Yang Huang, Hsuan Huang.
Writing – original draft: Yi-Hsin Lin, Hsuan Huang.
Writing – review & editing: Yi-Hsin Lin, Hsuan Huang.

References

[1] McElroy SL, Frye MA, Hellemann G, et al. Prevalence and correlates of eating disorders in 875 patients with bipolar disorder. J Affect Disord 2011;128:391–8.
[2] Terranova L, Busetto L, Vestri A, et al. Bariatric surgery: cost-effectiveness and budget impact. Obes Surg 2012;22:646–53.
[3] Reames BN, Finks JF, Bacal D, et al. Changes in bariatric surgery procedure use in Michigan, 2006–2013. JAMA 2014;312:959–61.
[4] English WJ, DeMaria EJ, Brethauer SA, et al. American Society for Metabolic and Bariatric Surgery estimation of metabolic and bariatric procedures performed in the United States in 2016. Surg Obes Relat Dis 2018;14:239–43.
[5] Sarwer DB, Cohn NI, Gibbons LM, et al. Psychiatric diagnoses and psychiatric treatment among bariatric surgery candidates. Obes Surg 2004;14:1148–56.
[6] Mitchell JE, King WC, Chen JY, et al. Course of depressive symptoms and treatment in the longitudinal assessment of bariatric surgery (LABS-2) study. Obesity (Silver Spring) 2014;22:1799–806.
Malhi GS, Gessler D, Outhred T. The use of lithium for the treatment of bipolar disorder: recommendations from clinical practice guidelines. J Affect Disord 2017;217:266–80.

Keck PEJr, McElroy SL. Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. J Clin Psychiatry 2002;63:3–11.

Hensel J, Selvadurai M, Anvari M, et al. Mental illness and psychotropic medication use among people assessed for bariatric surgery in Ontario, Canada. Obes Surg 2016;26:1531–6.

Tripp AC. Lithium toxicity after Roux-en-Y gastric bypass surgery. J Clin Psychopharmacol 2011;31:261–2.

Walsh K, Velling J. Lithium toxicity following Roux-en-Y gastric bypass. Bariatric Surg Practice Patient Care 2014;9:77–80.

Musfeldt D, Levinson A, Nykiel J, et al. Lithium toxicity after Roux-en-Y bariatric surgery. BMJ Case Rep 2016;2016: bcr2015214056.

Bingham KS, Thoma J, Hawa R, et al. Perioperative lithium use in bariatric surgery: a case series and literature review. Psychosomatics 2016;57:638–44.

Alam A, Raoud S, Recio FO. Lithium toxicity following vertical sleeve gastrectomy: a case report. Clin Psychopharmacol Neurosci 2016; 14:318–20.

Dahan A, Porat D, Azran C, et al. Lithium toxicity with severe bradycardia post sleeve gastrectomy: a case report and review of the literature. Obes Surg 2019;29:735–8.

Azran C, Wolk O, Zar M, et al. Oral drug therapy following bariatric surgery: an overview of fundamentals, literature and clinical recommendations. Obes Rev 2016;17:1050–66.

Seaman JS, Bowers SP, Dixon P, et al. Dissolution of common psychiatric medications in a Roux-en-Y gastric bypass model. Psychosomatics 2005;46:250–3.

Timmer RT, Sands JM. Lithium intoxication. J Am Soc Nephrol 1999;10:666–74.

Gitlin M. Lithium side effects and toxicity; prevalence and management strategies. Int J Bipolar Disord 2016;4:27.

Reiss RA, Haas CE, Karki SD, et al. Lithium pharmacokinetics in the obese. Clin Pharmacol Ther 1994;55:392–8.

Adityanjan , Mushu KR, Thampy A. The syndrome of irreversible lithium-effectuated neurotoxicity. Clin Neuropharmacol 2005;28:38–49.

Schou M. Long-lasting neurological sequelae after lithium intoxication. Acta Psychiatr Scand 1984;70:594–602.

Von Hartitzsch B, Hoench NA, Leigh RJ, et al. Permanent neurological sequelae despite haemodialysis for lithium intoxication. Br Med J 1972;4:757–9.